FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileEntropy Neurodynamics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ENP.AX
Entropy Neurodynamics Limited Stock AnalysisComprehensive stock analysis for Entropy Neurodynamics Limited (ENP.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisENP.AX
ENP.AX
Entropy Neurodynamics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ENP.AX
  1. Home
  2. Stocks
  3. Entropy Neurodynamics Limited

Entropy Neurodynamics Limited

🇦🇺ENP.AX•ASX

Entropy Neurodynamics Limited

🇦🇺ENP.AX•ASX

Your view on ENP.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Entropy Neurodynamics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Jason Alan Carroll
Headquarters
697 Burke Road, Camberwell, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Jason Alan Carroll
Headquarters
697 Burke Road, Camberwell, VIC, AU
Description

Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States.

The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness.

Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome.

Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Entropy Neurodynamics Limited. Starting points for Entropy Neurodynamics Limited: beta -0.36 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Entropy Neurodynamics Limited. Entropy Neurodynamics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Entropy Neurodynamics Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Entropy Neurodynamics Limited. Entropy Neurodynamics Limited has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ENP.AX12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ORKAOruka Therapeutics, Inc.HealthcareNASDAQ$6.5B
ORMPOramed Pharmaceuticals Inc.HealthcareNASDAQ$155.2M
ORPOFOSE Immunotherapeutics S.A.HealthcareOTC$260.3M
ORYZFOryzon Genomics S.A.HealthcareOTC$283.9M
OSRHWOSR Holdings, Inc.HealthcareNASDAQ$7.8M
OSTXOS Therapies IncorporatedHealthcareAMEX$42.0M
OTLCOncotelic Therapeutics, Inc.HealthcareOTC$21.2M
OTLKOutlook Therapeutics, Inc.HealthcareNASDAQ$94.9M
OVIDOvid Therapeutics Inc.HealthcareNASDAQ$415.2M
OXBOFOxford BioDynamics PlcHealthcareOTC$4.3M
OZYMFStrategic Partners A/SHealthcareOTC$3.7M
PAB.AXPatrys LimitedHealthcareASX—
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Entropy Neurodynamics Limited. Coverage tracks Entropy Neurodynamics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Entropy Neurodynamics Limited.

ENP.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1